In English | En español
Questions About Cancer? 1-800-4-CANCER

Childhood Soft Tissue Sarcoma Treatment (PDQ®)

  • Last Modified: 06/06/2014

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document

Changes to This Summary (06/06/2014)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Treatment of Newly Diagnosed Childhood Soft Tissue Sarcoma

Added Xiao et al. as reference 50 and Karita et al. as reference 95 and level of evidence 3iiDii.

Added text to state that a report from Spain indicated good control of severe thrombocytopenia of less than 30,000/mm3 in 11 patients with hemangioendothelioma or tufted angioma treated with weekly vincristine, and daily low-dose aspirin and ticlodipine (added level of evidence 3iiiA).

Treatment of Metastatic Childhood Soft Tissue Sarcoma

Added text to state that in a retrospective review, patients with synovial sarcoma and pulmonary metastases for whom it was possible to completely resect all metastatic lung lesions had better survival than did patients for whom it was not possible to achieve complete resections (cited Stanelle et al. as reference 9 and level of evidence 3iiiA).

Treatment of Progressive/Recurrent Childhood Soft Tissue Sarcoma

Added text to state that a phase I trial of pazopanib reported one partial response in a patient with desmoplastic small round cell tumor and prolonged disease stabilization in eight patients with recurrent sarcoma (cited Glade et al. as reference 5 and level of evidence 2Diii).

Added text to state that in 31 children and adolescents younger than 23 years with pulmonary metastases from synovial sarcoma, complete resection of lung metastases appeared to prolong survival when compared with ten other patients who were not considered candidates for metastasectomy (cited Stanelle et al. as reference 8 and level of evidence 3iiiA).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.